{"altmetric_id":12018428,"counts":{"readers":{"mendeley":5,"citeulike":0,"connotea":0},"total":{"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["241609659310100"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa6053cf058f61000666f","authors":["Brewer, George J.","Brewer, George J."],"doi":"10.1002\/jtra.10045","endpage":"199","first_seen_on":"2016-09-15T15:26:46+00:00","handle":"2027.42\/35052","handles":["2027.42\/35052"],"issns":["0896-548X","1520-670X"],"issue":"4","journal":"Journal of Trace Elements in Experimental Medicine","last_mentioned_on":1366974615,"links":["http:\/\/deepblue.lib.umich.edu\/handle\/2027.42\/35052"],"pdf_url":"http:\/\/deepblue.lib.umich.edu\/bitstream\/2027.42\/35052\/1\/10045_ftp.pdf","pubdate":"2016-09-15T20:03:00+00:00","publisher":"Wiley Subscription Services, Inc., A Wiley Company","startpage":"191","title":"Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation","type":"article","volume":"16","mendeley_url":"http:\/\/www.mendeley.com\/research\/copperlowering-therapy-tetrathiomolybdate-cancer-diseases-fibrosis-inflammation"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":6342401,"mean":5.8358158208258,"rank":5403657,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":6342401,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":100846,"mean":9.9402947890327,"rank":78875,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":100846,"percentile":1},"this_journal":{"total_number_of_other_articles":11,"mean":1.925,"rank":9,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":11,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":1,"mean":0,"rank":1,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":1,"Researcher":1,"Student  > Ph. D. Student":1,"Student  > Master":2},"by_discipline":{"Neuroscience":1,"Agricultural and Biological Sciences":3,"Unspecified":1}}},"geo":{"mendeley":{"ZA":1,"FR":1}}},"posts":{"facebook":[{"title":"Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=118552255009948&id=241609659310100","license":"public","citation_ids":[12018428,12018428],"posted_on":"2013-04-26T11:10:15+00:00","summary":"Title: \tCopper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation The University of Michigan has recently licensed the antiangiogenic uses of TM to Attenuon LLC, and Dr. Brewer has equity in Attenuon LLC\nAuthors:","author":{"name":"Biological Medicine","url":"https:\/\/www.facebook.com\/241609659310100","facebook_wall_name":"Australian Clinic of Biological Medicine","image":"https:\/\/graph.facebook.com\/241609659310100\/picture","id_on_source":"241609659310100"}}]}}